UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Developments in Ki67 and other biomarkers for treatment decision making in breast cancer

Annals of oncology, 2012-09, Vol.23 Suppl 10, p.x219-x227

2012

Volltextzugriff (PDF)

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

JNCI : Journal of the National Cancer Institute, 2011-11, Vol.103 (22), p.1656-1664

2011

Volltextzugriff (PDF)

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy

Annals of oncology, 2015-01, Vol.26 (1), p.75-80

2015

Volltextzugriff (PDF)

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Annals of oncology, 2015-08, Vol.26 (8), p.1685-1691

2015

Volltextzugriff (PDF)

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance

Oncogene, 2010-08, Vol.29 (33), p.4648-4657

2010

Volltextzugriff (PDF)

Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors

Annals of oncology, 2006-04, Vol.17 (4), p.584-587

2006

Volltextzugriff (PDF)

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

JNCI : Journal of the National Cancer Institute, 2008-10, Vol.100 (19), p.1380-1388

2008

Volltextzugriff (PDF)

Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial

JNCI : Journal of the National Cancer Institute, 2007-02, Vol.99 (4), p.283-290

2007

Volltextzugriff (PDF)

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status

Annals of oncology, 2006-05, Vol.17 (5), p.818-826

2006

Volltextzugriff (PDF)

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)

Annals of oncology, 2009-12, Vol.20 (12), p.1948-1952

2009

Volltextzugriff (PDF)

Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials

Annals of oncology, 2019-05, Vol.30, p.iii1-iii1

2019

Volltextzugriff (PDF)

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer

Annals of oncology, 2014-03, Vol.25 (3), p.605-610

2014

Volltextzugriff (PDF)

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer

Breast cancer research and treatment, 2017-07, Vol.164 (2), p.395-400

2017

Volltextzugriff (PDF)

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

The New England journal of medicine, 2017-11, Vol.377 (19), p.1836-1846

2017

Volltextzugriff (PDF)

The development of inhibitory control in preschool children: Effects of "executive skills" training

Developmental psychobiology, 2000-03, Vol.36 (2), p.161-174

2000

Volltextzugriff (PDF)

Polymorphisms Associated With Circulating Sex Hormone Levels in Postmenopausal Women

JNCI : Journal of the National Cancer Institute, 2004-06, Vol.96 (12), p.936-945

2004

Volltextzugriff (PDF)

HER2 testing in the UK: further update to recommendations

Journal of clinical pathology, 2008-07, Vol.61 (7), p.818-824

2008

Volltextzugriff (PDF)

Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer

Annals of oncology, 2013-01, Vol.24 (1), p.126-133

2013

Volltextzugriff (PDF)

Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies

JNCI : Journal of the National Cancer Institute, 2002-04, Vol.94 (8), p.606-616

2002

Volltextzugriff (PDF)

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

The Lancet (British edition), 1998-07, Vol.352 (9122), p.98-101

1998

Volltextzugriff (PDF)

Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial

Annals of oncology, 2018-10, Vol.29, p.viii70-viii70

2018

Volltextzugriff (PDF)

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

Annals of oncology, 2013-11, Vol.24 (11), p.2761-2766

2013

Volltextzugriff (PDF)

Studies of apoptosis in breast cancer

BMJ (Online), 2001-06, Vol.322 (7301), p.1528-1532

International edition, 2001

Volltextzugriff (PDF)

Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention

Annals of oncology, 2002-05, Vol.13 (5), p.669-678

2002

Volltextzugriff (PDF)

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer

Annals of oncology, 2011-08, Vol.22 (8), p.1770-1776

2011

Volltextzugriff (PDF)

1 – 25 von 398

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(391)
Mit Volltextzugriff
(346)

Publikationsform

Sprache

Englisch
(398)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Developments in Ki67 and other biomarkers for treatment decision making in breast cancer

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance

Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)

Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

The development of inhibitory control in preschool children: Effects of "executive skills" training

Polymorphisms Associated With Circulating Sex Hormone Levels in Postmenopausal Women

HER2 testing in the UK: further update to recommendations

Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer

Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

Studies of apoptosis in breast cancer

Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer

Aktive Filter

Suchergebnisse filtern